期刊
JOURNAL OF PATHOLOGY
卷 226, 期 2, 页码 365-379出版社
WILEY
DOI: 10.1002/path.2993
关键词
antisense oligonucleotides; siRNA; mRNA; gene silencing; therapeutics
资金
- National Institutes of Health [NIGMS 77253, 73042]
- Robert A Welch Foundation [I-1244]
- Natural Sciences and Engineering Research Council of Canada
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073042] Funding Source: NIH RePORTER
Synthetic nucleic acids are commonly used laboratory tools for modulating gene expression and have the potential to be widely used in the clinic. Progress towards nucleic acid drugs, however, has been slow and many challenges remain to be overcome before their full impact on patient care can be understood. Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) are the two most widely used strategies for silencing gene expression. We first describe these two approaches and contrast their relative strengths and weaknesses for laboratory applications. We then review the choices faced during development of clinical candidates and the current state of clinical trials. Attitudes towards clinical development of nucleic acid silencing strategies have repeatedly swung from optimism to depression during the past 20 years. Our goal is to provide the information needed to design robust studies with oligonucleotides, making use of the strengths of each oligonucleotide technology. Copyright (C) 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据